

Experiment Number: 20320 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

F1_M3

NTP Study Number: C20320
Lock Date: 01/12/2010
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.1.0_004
PWG Approval Date: NONE

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
------------------	---------	-----------	-----------	------------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident				1
Moribund Sacrifice	9	10	6	12
Natural Death	8	14	5	25
Survivors				
Moribund Sacrifice	1	1		
Terminal Sacrifice	32	25	39	12
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Gallbladder	(49)	(46)	(50)	(49)
Pigmentation, Hematoidin	1 (2%)			
Intestine Large, Cecum	(47)	(44)	(47)	(38)
Intestine Large, Colon	(47)	(46)	(50)	(40)
Diverticulum			1 (2%)	
Inflammation, Chronic Active		1 (2%)		
Intestine Large, Rectum	(47)	(46)	(50)	(41)
Intestine Small, Duodenum	(47)	(41)	(48)	(31)
Intestine Small, Ileum	(47)	(43)	(50)	(40)
Hyperplasia	1 (2%)			
Intestine Small, Jejunum	(47)	(44)	(49)	(38)
Diverticulum		1 (2%)		
Peyer's Patch, Hyperplasia, Lymphoid			1 (2%)	1 (3%)
Liver	(50)	(50)	(50)	(50)
Amyloid Deposition	1 (2%)			1 (2%)
Angiectasis			2 (4%)	1 (2%)
Basophilic Focus	9 (18%)	9 (18%)	6 (12%)	9 (18%)
Clear Cell Focus	11 (22%)	10 (20%)	25 (50%)	8 (16%)
Eosinophilic Focus	20 (40%)	33 (66%)	40 (80%)	14 (28%)
Fatty Change	1 (2%)	2 (4%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Fatty Change, Focal		1 (2%)	2 (4%)	1 (2%)
Fibrosis		1 (2%)		
Hemorrhage, Chronic			1 (2%)	
Inflammation	1 (2%)			
Inflammation, Granulomatous				1 (2%)
Mixed Cell Focus	7 (14%)	8 (16%)	12 (24%)	6 (12%)
Necrosis	1 (2%)	1 (2%)		6 (12%)
Pigmentation	1 (2%)			
Tension Lipidosis	3 (6%)		3 (6%)	2 (4%)
Bile Duct, Cyst			3 (6%)	4 (8%)
Bile Duct, Cyst, Multiple				1 (2%)
Hepatocyte, Atrophy		1 (2%)		
Hepatocyte, Hypertrophy	2 (4%)			
Hepatocyte, Necrosis		2 (4%)	1 (2%)	
Kupffer Cell, Pigmentation			2 (4%)	
Oval Cell, Hyperplasia			1 (2%)	
Periportal, Vacuolization Cytoplasmic			1 (2%)	2 (4%)
Serosa, Inflammation			1 (2%)	
Mesentery	(3)	(3)	(4)	(2)
Hemorrhage			1 (25%)	
Fat, Necrosis	2 (67%)	2 (67%)	2 (50%)	1 (50%)
Pancreas	(50)	(50)	(50)	(50)
Basophilic Focus			1 (2%)	
Acinus, Atrophy		1 (2%)	1 (2%)	
Arteriole, Fibrosis		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(49)	(50)	(49)
Hyperkeratosis			1 (2%)	1 (2%)
Infiltration Cellular, Mononuclear Cell	5 (10%)	8 (16%)	21 (42%)	27 (55%)
Inflammation	9 (18%)	10 (20%)	20 (40%)	26 (53%)
Ulcer	9 (18%)	9 (18%)	19 (38%)	28 (57%)
Epithelium, Hyperplasia	10 (20%)	13 (27%)	27 (54%)	28 (57%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Cyst	1 (2%)			
Hyperplasia	1 (2%)		2 (4%)	1 (2%)
Hyperplasia, Focal			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Tooth	(14)	(9)	(9)	(2)
Dysplasia	11 (79%)	8 (89%)	9 (100%)	2 (100%)
Inflammation	1 (7%)	1 (11%)	1 (11%)	

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			2 (4%)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	24 (48%)	20 (40%)	18 (36%)	8 (16%)
Inflammation				1 (2%)
Mineralization		2 (4%)		1 (2%)
Necrosis	1 (2%)			
Atrium, Thrombosis		1 (2%)	1 (2%)	
Myocardium, Necrosis	1 (2%)			
Pericardium, Fibrosis	1 (2%)			
Valve, Degeneration			1 (2%)	
Valve, Inflammation	2 (4%)	2 (4%)		

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Amyloid Deposition	1 (2%)			1 (2%)
Hyperplasia	3 (6%)	2 (4%)	1 (2%)	1 (2%)
Hypertrophy	2 (4%)			
Vacuolization Cytoplasmic		1 (2%)		
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)			
Hyperplasia	1 (2%)	2 (4%)		
Parathyroid Gland	(45)	(43)	(48)	(42)
Pituitary Gland	(50)	(48)	(48)	(50)
Thyroid Gland	(50)	(50)	(50)	(50)
Fibrosis				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Inflammation Follicle, Cyst	1 (2%)	1 (2%)	1 (2%)	
GENERAL BODY SYSTEM				
Peritoneum Inflammation, Suppurative	(0)	(2) 1 (50%)	(0)	(0)
GENITAL SYSTEM				
Coagulating Gland Inflammation Inflammation, Chronic Active	(3)	(4) 1 (25%)	(1) 1 (100%)	(0)
Epididymis Degeneration Granuloma Sperm Inflammation, Chronic Active	(50) 1 (2%)	(50)	(50) 1 (2%)	(50)
Preputial Gland Atrophy Ectasia Inflammation	(50) 2 (4%) 3 (6%)	(50) 2 (4%)	(50) 1 (2%) 1 (2%) 3 (6%)	(50) 5 (10%) 4 (8%)
Prostate Hyperplasia Inflammation Inflammation, Chronic Active Epithelium, Hyperplasia	(50) 1 (2%)	(50) 2 (4%) 1 (2%)	(50) 1 (2%)	(50) 1 (2%)
Seminal Vesicle Inflammation	(50)	(50)	(50)	(50) 1 (2%)
Testes Germinal Epithelium, Degeneration Interstitial Cell, Hyperplasia	(50) 5 (10%)	(50) 3 (6%) 1 (2%)	(50) 5 (10%)	(50) 3 (6%)

HEMATOPOIETIC SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Bone Marrow	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	1 (2%)
Hyperplasia	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Lymph Node	(3)	(0)	(2)	(0)
Lymph Node, Mandibular	(50)	(50)	(50)	(49)
Hyperplasia, Lymphoid	1 (2%)			
Lymph Node, Mesenteric	(50)	(49)	(50)	(49)
Atrophy				1 (2%)
Hemorrhage	1 (2%)	1 (2%)		
Hyperplasia, Lymphoid	1 (2%)	1 (2%)	4 (8%)	2 (4%)
Infiltration Cellular, Histiocyte			2 (4%)	
Inflammation		1 (2%)		2 (4%)
Necrosis		1 (2%)		
Necrosis, Lymphoid				1 (2%)
Spleen	(50)	(48)	(50)	(49)
Amyloid Deposition	1 (2%)			1 (2%)
Angiectasis				1 (2%)
Fibrosis				1 (2%)
Hematopoietic Cell Proliferation	1 (2%)	3 (6%)		5 (10%)
Hyperplasia, Lymphoid		1 (2%)		2 (4%)
Pigmentation, Hemosiderin		2 (4%)		
Lymphoid Follicle, Atrophy	3 (6%)	2 (4%)	1 (2%)	6 (12%)
Thymus	(47)	(45)	(41)	(48)
Atrophy	41 (87%)	42 (93%)	40 (98%)	40 (83%)
Cyst	1 (2%)			
Hyperplasia, Lymphoid	1 (2%)			
Thrombosis		1 (2%)		
Epithelial Cell, Hyperplasia		1 (2%)		

INTEGUMENTARY SYSTEM

Skin	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Ulcer	2 (4%)	4 (8%)	3 (6%)	4 (8%)
Subcutaneous Tissue, Necrosis		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibro-Osseous Lesion	1 (2%)			1 (2%)
Fibrosis				1 (2%)
Fibrous Osteodystrophy	1 (2%)			
Femur, Callus		2 (4%)		
Joint, Degeneration				4 (8%)
Vertebra, Fracture			1 (2%)	
Skeletal Muscle	(0)	(1)	(1)	(0)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Inflammation, Suppurative		1 (2%)		
Peripheral Nerve	(0)	(0)	(0)	(2)
Axon, Sciatic, Degeneration				1 (50%)
Spinal Cord	(0)	(0)	(0)	(2)
Axon, Degeneration				2 (100%)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)			
Infiltration Cellular, Histiocyte	1 (2%)		1 (2%)	
Inflammation	1 (2%)			2 (4%)
Pigmentation, Hemosiderin			1 (2%)	
Thrombosis	1 (2%)			
Alveolar Epithelium, Hyperplasia	5 (10%)	1 (2%)	6 (12%)	2 (4%)
Alveolar Epithelium, Hypertrophy	2 (4%)		1 (2%)	1 (2%)
Arteriole, Thrombosis			1 (2%)	
Bronchiole, Hyperplasia		1 (2%)		
Interstitial, Fibrosis		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Nose	(50)	(50)	(50)	(50)
Inflammation	5 (10%)	2 (4%)	3 (6%)	2 (4%)
Polyp, Inflammatory		1 (2%)		
Respiratory Epithelium, Hyperplasia	27 (54%)	25 (50%)	20 (40%)	12 (24%)
Respiratory Epithelium, Necrosis			1 (2%)	
Trachea	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Atrophy		1 (2%)	1 (2%)	
Cataract	2 (4%)		1 (2%)	1 (2%)
Inflammation	1 (2%)			1 (2%)
Cornea, Inflammation	1 (2%)	1 (2%)	1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)			
Hyperplasia	1 (2%)	1 (2%)		1 (2%)
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(48)
Cyst	1 (2%)			
Hydronephrosis		3 (6%)		1 (2%)
Infarct		1 (2%)		
Infiltration Cellular, Lymphocyte		1 (2%)	2 (4%)	
Nephropathy	41 (82%)	30 (60%)	32 (64%)	42 (88%)
Glomerulus, Amyloid Deposition	1 (2%)			1 (2%)
Papilla, Mineralization			1 (2%)	
Papilla, Necrosis	3 (6%)	1 (2%)		
Pelvis, Inflammation			1 (2%)	1 (2%)
Renal Tubule, Cyst	6 (12%)	2 (4%)	5 (10%)	6 (13%)
Renal Tubule, Cyst, Multiple				1 (2%)
Renal Tubule, Cytoplasmic Alteration		20 (40%)	47 (94%)	46 (96%)
Renal Tubule, Inflammation				4 (8%)
Renal Tubule, Mineralization	1 (2%)		1 (2%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Renal Tubule, Necrosis				4 (8%)
Renal Tubule, Pigmentation		5 (10%)	1 (2%)	2 (4%)
Urinary Bladder	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Transitional Epithelium, Hyperplasia	1 (2%)	1 (2%)		1 (2%)

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
--------------------	---------	-----------	-----------	------------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident				1
Moribund Sacrifice	6	8	3	7
Natural Death	4	11	11	38
Survivors				
Terminal Sacrifice	40	31	36	4
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Periesophageal Tissue, Inflammation				1 (2%)
Gallbladder	(47)	(49)	(50)	(50)
Inflammation			1 (2%)	
Intestine Large, Cecum	(48)	(46)	(45)	(21)
Lymphoid Tissue, Hyperplasia			1 (2%)	1 (5%)
Intestine Large, Colon	(50)	(48)	(50)	(43)
Serosa, Inflammation	1 (2%)			
Intestine Large, Rectum	(50)	(50)	(50)	(41)
Intestine Small, Duodenum	(47)	(46)	(42)	(18)
Perforation				1 (6%)
Epithelium, Vacuolization Cytoplasmic	1 (2%)			
Intestine Small, Ileum	(48)	(46)	(45)	(19)
Ulcer	1 (2%)		1 (2%)	
Intestine Small, Jejunum	(48)	(47)	(43)	(18)
Diverticulum	1 (2%)			
Epithelium, Vacuolization Cytoplasmic	1 (2%)			
Peyer's Patch, Hyperplasia	2 (4%)			
Liver	(50)	(50)	(49)	(49)
Angiectasis		1 (2%)	3 (6%)	
Basophilic Focus	8 (16%)	3 (6%)	3 (6%)	1 (2%)
Clear Cell Focus	3 (6%)	4 (8%)	3 (6%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Eosinophilic Focus	11 (22%)	16 (32%)	11 (22%)	1 (2%)
Fatty Change	6 (12%)	1 (2%)	1 (2%)	2 (4%)
Fatty Change, Focal		1 (2%)	3 (6%)	
Fibrosis				1 (2%)
Hematopoietic Cell Proliferation		2 (4%)	1 (2%)	
Infiltration Cellular, Lymphocyte	1 (2%)			
Infiltration Cellular, Polymorphonuclear		1 (2%)		
Inflammation, Chronic Active		5 (10%)	1 (2%)	
Mineralization			1 (2%)	
Mixed Cell Focus	4 (8%)	3 (6%)	3 (6%)	
Tension Lipidosis	4 (8%)	3 (6%)	4 (8%)	2 (4%)
Hepatocyte, Atrophy		1 (2%)		
Hepatocyte, Hypertrophy			1 (2%)	
Hepatocyte, Necrosis	3 (6%)	1 (2%)	1 (2%)	
Mesentery	(3)	(8)	(7)	(0)
Degeneration, Cystic	1 (33%)			
Inflammation, Focal		1 (13%)		
Fat, Inflammation	1 (33%)			
Fat, Necrosis	2 (67%)	6 (75%)	7 (100%)	
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(50)	(49)	(50)	(50)
Basophilic Focus			1 (2%)	
Infiltration Cellular, Lymphocyte			1 (2%)	
Inflammation	1 (2%)			
Acinus, Atrophy				2 (4%)
Salivary Glands	(50)	(48)	(50)	(50)
Atrophy			1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(48)
Foreign Body				1 (2%)
Hyperkeratosis	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Infiltration Cellular, Mononuclear Cell	2 (4%)	13 (26%)	33 (66%)	28 (58%)
Inflammation	2 (4%)	14 (28%)	41 (82%)	37 (77%)
Ulcer	2 (4%)	15 (30%)	40 (80%)	38 (79%)
Epithelium, Dysplasia			2 (4%)	
Epithelium, Hyperplasia	4 (8%)	16 (32%)	39 (78%)	39 (81%)
Epithelium, Metaplasia, Glandular			2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Stomach, Glandular	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell		1 (2%)		
Mineralization	1 (2%)			1 (2%)
Epithelium, Dysplasia			1 (2%)	
Serosa, Infiltration Cellular, Lymphocyte	1 (2%)			
Tongue	(1)	(0)	(0)	(0)
Tooth	(1)	(1)	(1)	(0)
Dysplasia	1 (100%)	1 (100%)	1 (100%)	

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(49)	(50)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	2 (4%)	5 (10%)	5 (10%)	
Mineralization		2 (4%)	1 (2%)	
Epicardium, Inflammation	2 (4%)			
Valve, Inflammation	1 (2%)	1 (2%)	1 (2%)	
Valve, Pigmentation, Hemosiderin	1 (2%)			

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(49)	(50)
Atrophy		1 (2%)		
Degeneration, Cystic	1 (2%)			
Hematopoietic Cell Proliferation		1 (2%)		
Hyperplasia	1 (2%)			
Hypertrophy	1 (2%)			
Adrenal Medulla	(50)	(50)	(49)	(50)
Hyperplasia	1 (2%)		1 (2%)	
Islets, Pancreatic	(50)	(49)	(50)	(50)
Hyperplasia	1 (2%)			1 (2%)
Parathyroid Gland	(34)	(41)	(42)	(43)
Hyperplasia, Focal			1 (2%)	
Pituitary Gland	(50)	(50)	(50)	(49)
Pigmentation, Hemosiderin	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
Pars Distalis, Hyperplasia		1 (2%)		1 (2%)
Thyroid Gland	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte C-cell, Hyperplasia			1 (2%)	
Follicle, Cyst		1 (2%)		
Follicular Cell, Hyperplasia	1 (2%)	1 (2%)		
GENERAL BODY SYSTEM				
Peritoneum	(0)	(1)	(0)	(0)
Inflammation, Suppurative		1 (100%)		
GENITAL SYSTEM				
Clitoral Gland	(50)	(50)	(49)	(48)
Ovary	(50)	(50)	(50)	(47)
Angiectasis		3 (6%)	1 (2%)	1 (2%)
Cyst			2 (4%)	
Hemorrhage	2 (4%)			
Inflammation		2 (4%)	2 (4%)	
Thrombosis		1 (2%)	1 (2%)	
Bursa, Cyst	2 (4%)		1 (2%)	1 (2%)
Follicle, Cyst	7 (14%)	6 (12%)	4 (8%)	1 (2%)
Periovarian Tissue, Necrosis	1 (2%)			
Oviduct	(1)	(0)	(1)	(0)
Inflammation	1 (100%)		1 (100%)	
Uterus	(50)	(50)	(50)	(50)
Dilatation			1 (2%)	
Inflammation	2 (4%)	1 (2%)		
Thrombosis	1 (2%)		1 (2%)	
Cervix, Inflammation		1 (2%)		
Endometrium, Hyperplasia, Cystic	35 (70%)	35 (70%)	29 (58%)	22 (44%)
Vagina	(0)	(1)	(0)	(0)
Epithelium, Necrosis		1 (100%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE FEMALE

0 mg/kg

250 mg/kg

500 mg/kg

1000 mg/kg

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	4 (8%)	3 (6%)	2 (4%)	
Myeloid Cell, Hyperplasia		3 (6%)		
Lymph Node	(1)	(5)	(3)	(1)
Mediastinal, Hyperplasia, Lymphoid	1 (100%)	1 (20%)		
Mediastinal, Inflammation				1 (100%)
Mediastinal, Necrosis, Lymphoid				1 (100%)
Renal, Ectasia			1 (33%)	
Renal, Hemorrhage			1 (33%)	
Lymph Node, Mandibular	(50)	(48)	(48)	(46)
Atrophy				1 (2%)
Infiltration Cellular, Plasma Cell	1 (2%)			
Lymph Node, Mesenteric	(50)	(50)	(50)	(47)
Atrophy			1 (2%)	
Ectasia			1 (2%)	
Hyperplasia, Lymphoid	1 (2%)		1 (2%)	
Spleen	(50)	(50)	(50)	(50)
Atrophy		1 (2%)	2 (4%)	
Hematopoietic Cell Proliferation	5 (10%)	4 (8%)	3 (6%)	2 (4%)
Hyperplasia, Lymphoid	10 (20%)	4 (8%)	6 (12%)	4 (8%)
Pigmentation, Hemosiderin	1 (2%)	1 (2%)		
Lymphoid Follicle, Atrophy	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Thymus	(50)	(50)	(48)	(50)
Atrophy	29 (58%)	24 (48%)	21 (44%)	29 (58%)
Hyperplasia, Lymphoid	1 (2%)			

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Ulcer	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
--------------------	---------	-----------	-----------	------------

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Fibro-Osseous Lesion	31 (62%)	19 (38%)	10 (20%)	6 (12%)
Osteopetrosis	1 (2%)			
Osteosclerosis			1 (2%)	
Joint, Degeneration	3 (6%)	1 (2%)	1 (2%)	

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell			1 (2%)	
Cerebrum, Neuron, Necrosis		1 (2%)		
Meninges, Infiltration Cellular, Lymphocyte			1 (2%)	

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Foreign Body	1 (2%)			
Hyperplasia, Lymphoid		1 (2%)		
Infiltration Cellular, Histiocyte	2 (4%)			
Infiltration Cellular, Lymphocyte	1 (2%)		1 (2%)	
Inflammation	1 (2%)	1 (2%)	1 (2%)	
Pigmentation, Hemosiderin		1 (2%)		
Alveolar Epithelium, Hyperplasia	1 (2%)		2 (4%)	1 (2%)
Interstitial, Fibrosis		1 (2%)		
Serosa, Hyperplasia			1 (2%)	
Serosa, Inflammation	1 (2%)			1 (2%)
Nose	(50)	(50)	(50)	(50)
Inflammation	1 (2%)	3 (6%)	2 (4%)	
Respiratory Epithelium, Hyperplasia	8 (16%)	3 (6%)	1 (2%)	
Trachea	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20320 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tetrabromobisphenol A

CAS Number: 79-94-7

Date Report Requested: 01/22/2013

Time Report Requested: 10:11:10

First Dose M/F: 08/07/07 / 08/06/07

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	250 mg/kg	500 mg/kg	1000 mg/kg
<hr/>				
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Cataract			1 (2%)	
Hemorrhage		1 (2%)		
Synechia			1 (2%)	
Cornea, Inflammation		2 (4%)	2 (4%)	
Harderian Gland	(50)	(49)	(50)	(50)
Hyperplasia		1 (2%)	1 (2%)	
Epithelium, Hyperplasia	1 (2%)			
<hr/>				
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(47)
Angiectasis			1 (2%)	
Infarct	1 (2%)			
Infiltration Cellular, Lymphocyte	2 (4%)		1 (2%)	
Metaplasia, Osseous	1 (2%)			
Nephropathy	18 (36%)	11 (22%)	23 (46%)	26 (55%)
Papilla, Mineralization	1 (2%)		1 (2%)	
Papilla, Necrosis	2 (4%)			
Renal Tubule, Cyst			2 (4%)	2 (4%)
Renal Tubule, Mineralization		3 (6%)	1 (2%)	1 (2%)
Urinary Bladder	(50)	(50)	(50)	(50)

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion